 |
| AI Generated Image For Representation Purpose |
Visakhapatnam is set to become the epicenter of a major revolution in Indian healthcare with the upcoming launch of India’s First Dedicated Nuclear Reactor for Medical Isotopes to Launch in Visakhapatnam by 2027. This landmark project, spearheaded by the Department of Atomic Energy (DAE) under the Atmanirbhar Bharat initiative, promises to drastically reshape cancer diagnostics and treatment across the nation.
Slashing Import Costs and Treatment Prices
India currently relies on imports for nearly 90% of its critical medical isotopes, resulting in an annual expenditure of approximately ₹500 crore. The new dedicated reactor will focus on the indigenous production of isotopes like Molybdenum-99 (Mo-99), which is essential for over 80% of all nuclear medicine procedures, particularly those involving the widely used imaging agent Technetium-99m.
The DAE projects that this domestic capacity will slash import dependency by half, leading directly to a significant reduction in patient costs. Treatments such as radioimmunotherapy are expected to become 30% cheaper, a massive relief for the estimated 1.5 million cancer patients who utilize nuclear medicine annually. This move is crucial, especially as cancer cases are projected to rise to 2 million by 2030.
A Game Changer for Healthcare Equity
The lack of domestic supply and the high cost of imports currently limit advanced diagnostics like PET scans to only about 200 centres nationwide. The Visakhapatnam facility aims to address this inequity. By ensuring a steady, affordable supply of high-quality radioisotopes, the project will enhance healthcare access, particularly for patients in rural and underserved areas.
The reactor is being established under a unique Public-Private Partnership (PPP) model, inviting private sector investment while BARC and NPCIL handle design and execution. This collaborative approach, combined with the government's push for skilled workforce training for nuclear medicine, positions India not just for self-sufficiency, but to emerge as a key regional player in the global nuclear medicine market.
While challenges in obtaining regulatory approvals for new nuclear facilities in India and training specialized personnel remain, the 2027 launch date marks a pivotal step toward healthcare independence and better, more affordable cancer care for all Indians.
Comments
Post a Comment